{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:34:49Z","timestamp":1786980889391,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703018"],"award-info":[{"award-number":["81703018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2022RC110"],"award-info":[{"award-number":["2022RC110"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2023KY614"],"award-info":[{"award-number":["2023KY614"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s10585-023-10227-5","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T06:02:36Z","timestamp":1692165756000},"page":"423-429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world"],"prefix":"10.1007","volume":"40","author":[{"given":"Min","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghui","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,16]]},"reference":[{"key":"10227_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE et al (2022) Cancer statistics. CA Cancer J Clin. 72:7\u201333","journal-title":"CA Cancer J Clin"},{"key":"10227_CR2","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.neo.2017.07.007","volume":"19","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Reid TR, Oronsky A et al (2017) What\u2019s New in SCLC? A review. Neoplasia. 19:842\u2013847","journal-title":"Neoplasia"},{"key":"10227_CR3","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/cncr.29098","volume":"121","author":"LA Byers","year":"2015","unstructured":"Byers LA, Rudin CM (2015) Small cell lung cancer: where do we go from here? Cancer. 121:664\u2013672","journal-title":"Cancer"},{"key":"10227_CR4","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1200\/JCO.1999.17.7.2092","volume":"17","author":"B Jeremic","year":"1999","unstructured":"Jeremic B, Shibamoto Y, Nikolic N et al (1999) Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol. 17:2092\u20132099","journal-title":"J Clin Oncol"},{"key":"10227_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","volume":"385","author":"BJ Slotman","year":"2015","unstructured":"Slotman BJ, van Tinteren H, Praag JO et al (2015) Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 385:36\u201342","journal-title":"Lancet"},{"key":"10227_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.lungcan.2017.03.007","volume":"108","author":"BJ Slotman","year":"2017","unstructured":"Slotman BJ, Faivre-Finn C, van Tinteren H et al (2017) Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: a secondary analysis of the phase III CREST trial. Lung Cancer. 108:150\u2013153","journal-title":"Lung Cancer"},{"key":"10227_CR7","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szczesna A et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell Lung Cancer. N Engl J Med. 379:2220\u20132229","journal-title":"N Engl J Med"},{"key":"10227_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","volume":"22","author":"JW Goldman","year":"2021","unstructured":"Goldman JW, Dvorkin M, Chen Y et al (2021) Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 22:51\u201365","journal-title":"Lancet Oncol"},{"key":"10227_CR9","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","volume":"38","author":"CM Rudin","year":"2020","unstructured":"Rudin CM, Awad MM, Navarro A et al (2020) Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line therapy for extensive-stage small-cell Lung Cancer: Randomized, Double-Blind, phase III KEYNOTE-604 study. J Clin Oncol. 38:2369\u20132379","journal-title":"J Clin Oncol"},{"key":"10227_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13014-020-01595-3","volume":"15","author":"L Kasmann","year":"2020","unstructured":"Kasmann L, Eze C, Taugner J et al (2020) Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy. Radiat Oncol. 15:167","journal-title":"Radiat Oncol"},{"key":"10227_CR11","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE et al (2022) Five-year survival outcomes from the PACIFIC Trial: Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 40:1301\u20131311","journal-title":"J Clin Oncol"},{"key":"10227_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","volume":"23","author":"Q Zhou","year":"2022","unstructured":"Zhou Q, Chen M, Jiang O et al (2022) Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 23:209\u2013219","journal-title":"Lancet Oncol"},{"key":"10227_CR13","unstructured":"Parsons LS Performing a 1:n case-control match on propensity score. Available at: https:\/\/support.sas.com\/resources\/papers\/proceedings\/proceedings\/sugi29\/165-29.pdf"},{"key":"10227_CR14","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","volume":"19","author":"AKP Ganti","year":"2021","unstructured":"Ganti AKP, Loo BW, Bassetti M et al (2021) Small cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 19:1441\u20131464","journal-title":"J Natl Compr Canc Netw"},{"key":"10227_CR15","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 394:1929\u20131939","journal-title":"Lancet"},{"key":"10227_CR16","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1056\/NEJMoa071780","volume":"357","author":"B Slotman","year":"2007","unstructured":"Slotman B, Faivre-Finn C, Kramer G et al (2007) Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 357:664\u2013672","journal-title":"N Engl J Med"},{"key":"10227_CR17","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"328","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Han L, Wu L et al (2022) Effect of First-Line Serplulimab vs Placebo added to Chemotherapy on Survival in patients with extensive-stage small cell Lung Cancer: the ASTRUM-005 Randomized Clinical Trial. JAMA. 328:1223\u20131232","journal-title":"JAMA"},{"key":"10227_CR18","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS et al (2021) Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung Cancer treated with atezolizumab, carboplatin, and Etoposide (IMpower133). J Clin Oncol. 39:619\u2013630","journal-title":"J Clin Oncol"},{"key":"10227_CR19","doi-asserted-by":"publisher","first-page":"9255","DOI":"10.1038\/s41598-017-09775-0","volume":"7","author":"LM Xu","year":"2017","unstructured":"Xu LM, Cheng C, Kang M et al (2017) Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer. Sci Rep. 7:9255","journal-title":"Sci Rep"},{"key":"10227_CR20","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1007\/s00432-019-03000-3","volume":"145","author":"H Zhang","year":"2019","unstructured":"Zhang H, Deng L, Wang X et al (2019) Metastatic location of extensive stage small-cell lung cancer: implications for thoracic radiation. J Cancer Res Clin Oncol. 145:2605\u20132612","journal-title":"J Cancer Res Clin Oncol"},{"key":"10227_CR21","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jtho.2019.10.001","volume":"15","author":"JW Welsh","year":"2020","unstructured":"Welsh JW, Heymach JV, Chen D et al (2020) Phase I trial of Pembrolizumab and Radiation Therapy after induction chemotherapy for extensive-stage small cell Lung Cancer. J Thorac Oncol. 15:266\u2013273","journal-title":"J Thorac Oncol"},{"key":"10227_CR22","doi-asserted-by":"publisher","first-page":"100883","DOI":"10.1016\/j.adro.2021.100883","volume":"7","author":"BH Diamond","year":"2022","unstructured":"Diamond BH, Verma N, Shukla UC et al (2022) Consolidative thoracic Radiation Therapy after First-Line chemotherapy and immunotherapy in extensive-stage small cell Lung Cancer: a Multi-Ins titutional Case Series. Adv Radiat Oncol. 7:100883","journal-title":"Adv Radiat Oncol"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-023-10227-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-023-10227-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-023-10227-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T07:08:13Z","timestamp":1694416093000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-023-10227-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,16]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10227"],"URL":"https:\/\/doi.org\/10.1007\/s10585-023-10227-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2891756\/v1","asserted-by":"object"}]},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,16]]},"assertion":[{"value":"4 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}